• Publications
  • Influence
Neuroinflammation: friend and foe for ischemic stroke
TLDR
How neuroinflammation has both beneficial as well as detrimental roles and recent therapeutic strategies to combat pathological responses are discussed and the time-dependent role of inflammatory factors could help in developing new diagnostic, prognostic, and therapeutic neuroprotective strategies for post-stroke inflammation. Expand
The Neuroprotective Effects of Histamine H3 Receptor Antagonist E177 on Pilocarpine-Induced Status Epilepticus in Rats
TLDR
It is suggested that the newly developed H3R antagonist E177 provides neuroprotection in a preclinical PLC-induced SE in rats, highlighting the histaminergic system as a potential therapeutic target for the therapeutic management of SE. Expand
The dual-active histamine H3 receptor antagonist and acetylcholine esterase inhibitor E100 ameliorates stereotyped repetitive behavior and neuroinflammation in sodium valproate induced autism in mice.
TLDR
This is the first in vivo demonstration of the effectiveness of a potent dual-active H3R antagonist and AChE inhibitor against autistic-like repetitive compulsive behaviors and neuroinflammation, and provides evidence for the role of such compounds in treating ASD. Expand
Lycopodium Attenuates Loss of Dopaminergic Neurons by Suppressing Oxidative Stress and Neuroinflammation in a Rat Model of Parkinson’s Disease
TLDR
Robtenone-injected rats that were orally treated with lycopodium were protected against dopaminergic neuronal loss by diminishing the expression of matrix metalloproteinase-3 and MMP-3, as well as reduced activation of microglia and astrocytes, suggesting that Lyc has the potential to be further developed as a therapeutic candidate for PD. Expand
Diabetes as a risk factor for Alzheimer’s disease in the Middle East and its shared pathological mediators
TLDR
The incidence of AD and DM in the Middle East and the possible link between insulin signaling and ApoE carrier status on Aβ aggregation, tau hyperphosphorylation, inflammation, oxidative stress and mitochondrial dysfunction in AD is reviewed. Expand
Antagonism of Histamine H3 receptors Alleviates Pentylenetetrazole-Induced Kindling and Associated Memory Deficits by Mitigating Oxidative Stress, Central Neurotransmitters, and c-Fos Protein
TLDR
The potential of H3R antagonist E177 as adjuvant to antiepileptic drugs with an added advantage of preventing cognitive impairment is suggested, highlighting the H3Rs as a potential target for the therapeutic management of epilepsy with accompanied memory deficits. Expand
Valeric Acid Protects Dopaminergic Neurons by Suppressing Oxidative Stress, Neuroinflammation and Modulating Autophagy Pathways
TLDR
It is found that Val prevented rotenone induced upregulation of pro-inflammatory cytokine oxidative stress, and α-synuclein expression with subsequent increase in vital antioxidant enzymes, and could be further developed as a potential therapeutic candidate for treatment of PD. Expand
The Dual-Active Histamine H3 Receptor Antagonist and Acetylcholine Esterase Inhibitor E100 Alleviates Autistic-Like Behaviors and Oxidative Stress in Valproic Acid Induced Autism in Mice
TLDR
The results demonstrate the promising effects of E100 on in-vivo VPA-induced ASD-like features in mice, and provide evidence that a potent dual-active H3R antagonist and AChE inhibitor (AChEI) is a potential drug candidate for future therapeutic management of autistic-like behaviours. Expand
Role of Functional Biomarkers to Identify Early Vitamin B12 Deficiency in Patients with Sleeve Gastrectomy: A Cross-Sectional Study
TLDR
This is the first report of serum levels of B12 and its functional biomarkers in postoperative LSG patients among a local population from the UAE, and revealed significant alterations of the B12 biomarkers, total B12, MMA, and tHcy in one-year postoperativeLSG patients. Expand
Health Outcomes Research of Novel Disease Modifying Medications in Alzheimer’s Disease and Cost Burden of Early Onset Dementia
TLDR
The objective was to estimate cost-effectiveness of novel disease-modifying medication (DMM) compared to standard medication currently used in the treatment of Alzheimer’s disease and hypothesis was that the introduction of DMM will have minimal budgetary changes to direct costs incurred by payers. Expand
...
1
2
...